ARQTArcutis Biotherapeutics Inc
ARQT
Arcutis Biotherapeutics Inc2,461
Mkt Cap
$2.93BVolume
1.38M52W High
$31.7752W Low
$12.42PE Ratio
-167.41ARQT Fundamentals
Price
$24.17Prev Close
$23.42Open
$23.8150D MA
$23.76Beta
1.43Avg. Volume
1.05MEPS (Annual)
-$0.1269P/B
15.24Rev/Employee
$1.06M$3,587.81
Compact View
Not available
Not available
Poll
Earnings Recap
• Reported GAAP EPS of -$0.09 up 55.00% YoY • Reported revenue of $105.4M up 60.07% YoY
Bullish
Arcutis Biotherapeutics Inc achieved significant product revenue growth, driven by strong demand and multiple ZORYVE approvals across indications and age groups, while advancing its ARQ-234 pipeline into clinical trials.
Bearish
Arcutis Biotherapeutics Inc faces ongoing significant annual losses and an accumulated deficit, coupled with substantial funding risk if capital resources prove insufficient, and exposure to increased interest expense on its floating-rate debt.